65193-87-5Relevant articles and documents
1, 4-dihydro-1, 6-naphthyridine derivative, pharmaceutical composition of 1, 4-dihydro-1, 6-naphthyridine derivative, and application thereof
-
Paragraph 0058-0060, (2021/08/07)
The invention relates to a 1, 4-dihydro-1, 6-naphthyridine derivative, a pharmaceutical compositio of the 1, 4-dihydro-1, 6-naphthyridine derivative, and application of the 1, 4-dihydro-1, 6-naphthyridine derivative and the pharmaceutical composition of the 1, 4-dihydro-1, 6-naphthyridine derivative to treatment and prevention of cardiovascular, metabolic and kidney related diseases, and belongs to the field of medicine.
Barnidipine hydrochloride compound and preparation method thereof
-
Paragraph 0042; 0043; 0044; 0056; 0057; 0058, (2019/01/16)
The invention discloses a barnidipine hydrochloride compound and a preparation method thereof. The preparation method comprises the following steps: (1) using 3-hydroxypropionitrile to react with diketene, to obtain an intermediate 1; (2) enabling the intermediate 1 to react with m-nitrobenzaldehyde and Beta-amino methyl crotonate, to obtain an intermediate 2; (3) enabling the intermediate 2 to behydrolyzed by strong base, to obtain an intermediate 3; (4) enabling the intermediate 3 to be resolved by chiral organic base, to obtain an intermediate 4; (5) enabling the intermediate 4 to react with thionyl chloride, (S)-1-benzyl-3-pyrrolidinol, and HCI ethanol solution, to obtain a crude product of barnidipine hydrochloride; and (6) performing ethyl alcohol pulping and refining, and ethyl alcohol recrystallization on the crude product of the barnidipine hydrochloride, to obtain the barnidipine hydrochloride.
Compound and its as L-type calcium channel blocker or/and application of acetylcholine esterase inhibitors
-
Paragraph 0414-0415, (2016/10/07)
Disclosed in this invention are compounds and the uses as L-type calcium channel blocker and/or acetylcholinesterase inhibitor thereof. The uses of said compounds in the manufactures of a medicament for the treatment of cardiovascular diseases, apoplexy or senile dementia are also disclosed in the present invention.